Product Information
TEMAZEPAM 30 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $0.0893 per EA under NDC 00228207750. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 7, 1987. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228207750
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TEMAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA071620FDA Approved
8/7/1987
TE Code
AB
On Market Since
9/30/1990
Pharmacological Classes
Price Statistics
The NADAC for TEMAZEPAM 30 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 15.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0893 per EA |
|---|---|
| All-time high | $0.1075 (Sep 15, 2021) |
| All-time low | $0.0689 (Apr 18, 2018) |
| 52-week high | $0.0926 |
| 52-week low | $0.0893 |
| Median price | $0.0889 |
| Average price | $0.0878 |
| Largest weekly change | -20.4% (Nov 20, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Temazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TEMAZEPAM 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TEMAZEPAM 30 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $0.0893 per EA (NDC 00228207750), effective Sep 30, 2026.
How has the price of TEMAZEPAM 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TEMAZEPAM 30 MG CAPSULE has risen 15.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TEMAZEPAM 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for TEMAZEPAM 30 MG CAPSULE has ranged from a low of $0.0689 (Apr 18, 2018) to a high of $0.1075 (Sep 15, 2021), with a median of $0.0889 per EA.
Are there cheaper alternatives to TEMAZEPAM 30 MG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TEMAZEPAM 30 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures TEMAZEPAM 30 MG CAPSULE?
TEMAZEPAM 30 MG CAPSULE (NDC 00228207750) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.